Breaking News

As part of the collaboration, Johnson & Johnson will build a lung cancer center at Boston University and build upon programs linked to cancer research.


The designation will help the company accelerate the process of bringing the opioid addiction risk test through regulatory review and clearance.

Using genotype and blood plasma protein information for thousands of healthy individuals, researchers documented variants influencing plasma protein levels.

Exome sequencing on tumors from metastatic, castration-resistant prostate cancer cases responding to immunotherapy led to homologous recombination defects.

The agreement grants MDxHealth the rights to manufacture and market the phosphodiesterase-4D7 biomarker as a prognostic test.

Microbiotica will use its metagenomics microbiome platform to help Genentech develop biomarkers, targets, and medicines for inflammatory bowel disease.

The company is developing a platform for synthesizing biomedical knowledge from scientific, regulatory, and commercial literature.

As part of the collaboration, Texas A&M veterinarians will send canine urine samples to LexaGene for testing on its LX6 pathogen detection instrument.

Makers of genetic health risk tests will only need one FDA review before commercializing tests, with some exceptions.

New trial data presented at ASCO highlights the utility of checkpoint inhibitors, alone or with chemotherapy, across PD-L1 expression groups.

The partners will develop next-generation sequencing-based tests for precision cancer treatment for the Asian market.

The firms will combine Thermo Fisher's mass spec systems with Evosep's liquid chromatography to develop high-throughput clinical proteomic methods.

Formerly known as NetBio, the firm is now the first to gain approval under the new standards of the Rapid DNA Act of 2017.

The study solidified how doctors should interpret and act upon an intermediate result from the breast cancer risk test in how to treat early-stage patients.

The plan seeks to modernize the US biomedical data handling infrastructure, in order to to keep up with the explosive growth in information from genomics research.

In a pan-cancer analysis, Lynch syndrome genes were mutated more often than anticipated in tumors with high or intermediate levels of microsatellite instability.

The initiative will promote the clinical implementation of precision medicine with an initial focus on rare diseases.

The test is Micronics’ first to receive FDA clearance, and the company is pursuing CE marking for it and the PanNAT system.

The companion diagnostic test identifies patients taking the Novartis drug Tasigna who are candidates for treatment-free remission monitoring.

The partners will use NanoString's PanCancer panel in NCI-sponsored trials to characterize immune activity and develop potentially predictive gene signatures.

Last week, GenomeWeb's readers were most interested in Myriad Genetics' acquisition of Counsyl for $375 million.

Rosetta had disclosed that it intended to file for bankruptcy after its merger with Genoptix was not completed as planned.

The China FDA has approved Vela's cell-free DNA extraction kit, which can be coupled with RT-PCR or NGS workflows for further analysis.

A phase 1 study from MD Anderson saw a modest increase in overall and progression-free survival in cancer patients molecularly matched to treatment.

The institutes will explore the use of Inivata's liquid biopsy platform to analyze ctDNA to measure minimal residual disease in NSCLC patients.

Pages

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.